We report on our experience with this novel compound focusing on its pharmacokinetics and pharmacodynamics after induction polychemotherapy. These analyses were performed in the context of a phase II study and were approved by the local ethics committee. Prior to initiation of study medication, all patients gave their written informed consent. Seven days after the end of induction chemotherapy comprising high-dose cytarabine and mitoxantron, 6 mg of pegfilgrastim (Neulasta) was administered subcutaneously in patients showing complete blast clearance in routine bone marrow aspiration. A second injection was scheduled for those patients remaining leukopenic (that is, leukocytes o1 G l -1
In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML 4 NPM1 mutations characteristically generate mutants that localize aberrantly in the cytoplasm of leukaemic cells, 1 hence, the term NPMc þ (cytoplasmic-positive) AML. Cytoplasmic NPM accumulation is caused by changes of tryptophan(s) 288 and 290 (or only 290) and creation of a new nuclear export signal (NES) motif at the C-terminus of the NPM mutant. 5 Although the transforming potential of the NPM leukaemic mutants is yet to be proven, the observation that mutants retaining tryptophan 288 always combine with the strongest C-terminus NES motif reveals mutational selective pressure toward enhanced NPM export into cytoplasm, 6 pointing to this event as critical for leukaemogenesis. 4 About 80% of NPM1-mutated AML bear 'mutation A', 1, 4 that is, a tandem duplication of a TCTG tetranucleotide at positions 956-959 of NPM1. Intriguingly, tandem duplications seem to have played a role in evolution of biological diversity, 7 as expansions and contractions of repeats in critical genes are associated with great morphological diversity (for example, canine limbs and skulls). 8 In humans, generation of DNA repeats is an ongoing process in tissues, 9 and duplications of very short repetitive sequences contribute significantly to the generation of insertion mutations. Indeed, repeat instability, a major mutation form, is linked to several neurological disorders. 9, 10 It is not known whether tandem duplication of short nucleotide sequences targeting genes other than NPM1 can generate NES motifs and ultimately leads to aberrant cytoplasmic dislocation and accumulation of unidentified mutated proteins. Therefore, we developed a genome-wide computational analysis to assess whether duplication of 3-6 nucleotide combinations could lead to generation of a known NES motif in any human gene. We also used immunohistochemistry to study NPM nucleo-cytoplasmic transport abnormalities in 3017 samples of different human tumours. Our results strongly suggest that, in the human genome, duplication-linked generation of a NES motif appears to be unique to the NPM1 mutation, and confirm that cytoplasmic expression of NPM leukaemic mutants is restricted to AML.
To explore hypothetical duplication events causing known NES signals in the human genome, we designed a computational approach (Figure 1 ) based on a customized software (Supplementary Material and Supplementary Figure 1) . We first accessed NES sequences in the NES database, 11 which is available online at http://www.cbs.dtu.dk/databases/NESbase (last accessed on 3 July 2007). The current version of the database contains 75 protein sequences carrying experimentally validated NES signals. Our computational analysis was restricted to motifs that contain amino acids both necessary and sufficient for nuclear export. Moreover, for our study, we only included sequences containing up to 15 amino acids, so as to prevent a combinatorial explosion induced by genetic code redundancy during retrotranslation. Some signals that could not be clearly identified as contiguous amino acid sequences were excluded, since they were short sequences of a few annotated residues interwoven with the non-annotated ones. A total of 28 NES sequences were retrotranslated, taking all possible codon combinations into account. Besides these 28 dabatase NES motifs, we also analysed the C-terminus of 23 known NPM1 leukaemic mutants.
After retrotranslation, each signal was processed in a search for tandem duplications with a period of 3-6 nucleotides as well as exact multiple duplications, for example, 'TCTG TCTG TCTG'. When a duplication was identified, its last repeat was deleted and its DNA sequences were matched against human genome coding sequences (NCBI repository: ftp://ftp.ncbi.nih. gov/genomes/H_sapiens/RNA/rna.fa.gz, last accessed on 30 July 2007), in an attempt to find wild-type genes with the potential to generate NES after the duplication events. The set of genes was analysed to exclude artefacts, that is, rediscovery of our original NES.
The results of computational analysis are reported in Table 1 . Notably, in the search starting from the NPM mutational variants, we recovered only the NPM1 gene (leukaemic mutant 'A'), which was first described by Falini et al. 1 This finding served to validate our approach. The other occurrences reported in Table 1 were filtered out by the last computational step. In particular, NES-00018, NES-00019, NES-00023, NES-00041.1 and NES-00041.2, all result in matches with genes that physiologically contain the same NES signal.
Our findings so far strongly suggest that, out of the entire human genome, only the NPM1 gene fulfils the requirements for an 'ideal' site for duplication encoding for an NES motif. However, since not all NES motifs in nature (and diseases) are known and since our analysis was restricted to those containing stretches of up to 15 amino acids, we cannot exclude that other genes may theoretically undergo this process.
The unique mechanism underlying generation of a new NES motif, that leads (in concert with C-terminus tryptophans alterations) to aberrant cytoplasmic NPM expression is not the only distinguishing feature of NPM1 mutations. In fact, immunohistochemical studies 1, 12 support the view that, among human tumours, altered nucleo-cytoplasmic NPM transport due to NPM1 mutations is specific for AML. To further confirm these findings, we extended our immunohistochemical investigations 1, 12 in human tumours to a total of 3017 bioptic specimens, which included 1123 new de novo AML cases and also new tumour types. The immunohistochemical results on the tumours so far investigated in this and previous studies are shown in Supplementary Table 1. Cytoplasmic NPM expression (indicative of NPM1 mutations) was restricted to 386/1123 (34.3%) of de novo AML. A representative example of NPMc þ AML is shown in Figures 2a and b . All other tumours exhibited nucleusrestricted NPM positivity, which is fully predictive of wild-type NPM1. 4 Immunohistochemistry allowed the study of tumour samples even under circumstances that would have presented difficulties for NPM1 mutation analysis, that is, small percentage of tumour cells (for example, Hodgkin's disease; Figure 2d ), inability to collect neoplastic cells because of dry-tap (such as in primary myelofibrosis or in hairy cell leukaemia), small sized bioptic samples or lack of fresh material. Representative examples of NPM immunostaining pattern of various types of tumours other than NPMc þ AML are shown in Figure 2(c-f) .
These immunohistochemical studies and recent reports of mutational analysis of solid tumours, 13 clearly point to NPM1 mutations and consequent cytoplasmic dislocation of nucleo- Wild-type genes found in the genome (6 sequences)
NES-generation candidates (1 sequence)

Figure 1
Flow chart summarizing our computational prediction of putative NES generation through tandem duplication in the human genome. The number of sequences that will be processed at steps 4 and 5 refers to repeat units of length 3. NES: nuclear export signal.
Letters to the Editor phosmin as an event specifically restricted to AML. The reason why NPM1, an ubiquitously expressed gene that encodes for one of the most abundant nucleolar proteins, is selectively associated with myeloid but not lymphoid leukaemias, 12 remains a mistery.
In conclusion, computational analysis and immunohistochemistry indicate that NPM1 mutation is a unique genetic event that is specific to AML. These findings, taken together with the distinctive biological and clinical features of NPMc þ AML, 4 further point to NPM1 mutations as the genetic marker of a new leukaemia entity that should be considered for inclusion in the upcoming WHO Classification.
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V617F point mutation has been described in 65-97% of patients with polycythemia vera (PV).
1 Previously, 17 phenotypical cases of PV from a large group of patients from three institutions were initially reported as JAK2 V617F negative. 2 These cases were reanalyzed in detail to determine the cause, if any, of the JAK2 V617F negativity. Reasons for this initial negativity included inaccurate clinical diagnosis, relatively insensitive laboratory techniques, insufficient material for retesting, and possible treatment effect. It was predicted that when tested appropriately, JAK2 mutations would be found in all new cases of PV. 2 To address the assay sensitivity issue, we studied a total of 105 PV cases diagnosed by Polycythemia Vera Study Group criteria using three different assays of distinct analytical sensitivity. We defined the sensitivity by mixing DNA from JAK2 V617F -containing human erythroid leukemia cells (HEL) with that from normal peripheral blood mononuclear cells, so that 1% sensitivity would detect one part of HEL DNA in 100 parts of normal DNA. The first method used was pyrosequencing, which involves synthetic nucleotide extension by DNA polymerase. The method reliably detects JAK2 V617F when the mutant allele is greater than 5%. 1 The second method was a standard amplification refractory mutation system (ARMS) PCR assay, which detects the mutant allele when it occupies more than 1% of total DNA. 3 The third method was a modified highly sensitive ARMS assay. 4 The analytic sensitivity of the modified ARMS assay reaches 0.1% and has a false positive rate of less than 0.01% (we found 1 positive case in 300 individuals without myeloid disorders). 5 Of 105 PV cases, the combination of all three assays detected the JAK2 V617F allele in 104. In the remaining case, the JAK2 exon 12 deletion (E543-D544 del) was detected. Therefore, mutations in JAK2 have been detected in 100% of 105 PV patients examined.
Of the eight patients who were not detected by the pyrosequencing method, all had been treated; four had been on interferon for a median of 13 years, two on imatinib for 3 years and two had been treated by phlebotomy for 7 and 28 months, respectively. Therefore, sensitive methods such as ARMS-PCR assays presented here may be of particular value in patients treated for some time with different modalities.
Although it has been realized that a sensitive assay is required to identify the JAK2 V617F mutation in PV patients, 2 it has never been shown which level of sensitivity is adequate, that is 5, 1 or 0.1%. To address this issue, in 33 patients, we compared the test results in parallel with three assays. Of these patients, modified ARMS detected JAK2 V617F in all 33 (100%), whereas standard ARMS detected JAK2 V617F in 30 (91%) and pyrosequencing detected JAK2 V617F in 27 (82%). Our results suggest that an assay with 0.1% sensitivity is required to detect adequately JAK2 V617F in all PV patients. These results also suggest that an assay with a sensitivity of 5%, as currently offered by many laboratories, might miss a number of PV patients, especially those who have been treated. 
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